Pronfocus: 03/03/08

Monday, March 03, 2008

Kiekert Heralds new development and production hub in China

Heiligenhaus and Changsu (ANTARA News/PRNewswire-AsiaNet) - Kiekert, leading supplier of latch systems for the automotive industry is building its first factory in China.

Kiekert has chosen the city of Changshu, in the vicinity of Shanghai, as its first own development and production center. Thus, our international group is accommodating requirements of globally operating automotive manufacturers for the worldwide presence of their suppliers.

CEO Dr. Karl Krause states, "In signing the contract today we have laid the foundation to start up the production according to schedule in the course of this year."

More than 1,000 employees are to work in this factory by 2011. The development and production hub will bundle the advantages of the Asian sourcing markets with the favourable production conditions in China. A significant expansion of the product development will be linked to the size of the factory.

Both functions will support our customers locally.
Kiekert is strictly pursuing its strategy of a worldwide local presence.

Krause states: "Kiekert is currently implementing the transition from a global supplier to a global manufacturer. In the future, the automotive industry can rely even more on finding us in the neighbourhood of their production facilities - anywhere in the world."

Note to editors: Kiekert dominates the side door latch market segment for passenger cars and light commercial vehicles and is the leading latch manufacturer worldwide.

Kiekert controls more than 16 per cent of the global market volume for side door latches, which totals 220 million units per year.

Kiekert employs around 4,300 people worldwide, including some 1,350 at corporate headquarters in Heiligenhaus, Germany. Kiekert operates production facilities in Germany, the Czech Republic, the USA and Mexico. It also has sales offices and affiliates in the major automotive industry centres and growth markets. Kiekert group posted global revenues of more than EUR 500 million in 2007.

Press Contact:
Sven van Zoest Tel: +49-2056-15-8144 Fax: +49-02056-15-6719
Sven.vanzoest@kiekert.com Kiekert AG Public
Affairs Hoseler Platz 2 D- 42579 Heiligenhaus

SOURCE: Kiekert AG
CONTACT:
Sven van Zoest, Tel: +49-2056-15-8144, Fax: +49-02056-15-6719, Sven.vanzoest@kiekert.com

University of Western Sydney counts on Verizon Business security

Sydney (ANTARA News/PRNewswire-AsiaNet) - Managed Security

Services Enhance Network Protection and Availability The University of Western Sydney (UWS) has chosen Verizon Business to help protect its network from internal and external security threats.

Verizon Business has been awarded a three-year contract to provide managed security services, including network monitoring, firewall and intrusion detection, over UWS' internal network, extranet and Internet perimeter.

UWS is one of Australia's largest universities, with more than 35,000 students and 2,500 staff on six campuses in Greater Western Sydney.

Darren Geddes, IT security coordinator for UWS, said: "With thousands of students and staff members accessing our internal network and extranet every day, effective security is vital to protect our overall integrity -- any breach could affect both academic research and teaching results. Verizon Business Security Solutions' expertise, resources and proven capabilities give us enhanced network visibility and protect against external threats, without the need to invest in additional staff resources."

Paul O'Rourke, regional vice president, Verizon Business Security Solutions, said: "Our customers need robust yet flexible security solutions. Verizon Business Security Solutions has the expertise and experience needed to design, develop and implement complete security strategies tailored to our customers' individual needs."

"Our managed security services enable our customers to focus on their business objectives, safe in the knowledge that their security, from the network through to the application, is in expert hands."

Enterprises and government agencies rely on Verizon Business to help them manage security risk and protect critical company assets. Verizon Business Security Solutions offers a comprehensive portfolio of security services that includes threat and vulnerability management, identity management, security and compliance programs, and security strategy and consultation. More than 1,100 security professionals around the globe deliver these offerings through a range of managed services, professional services and products.

About Verizon Business

Verizon Business, a unit of Verizon Communications (NYSE: VZ), is a leading provider of advanced communications and information technology (IT) solutions to large-business and government customers worldwide. Combining unsurpassed global network reach with advanced communications, security and other professional service capabilities, Verizon Business delivers innovative and seamless business solutions to customers around the world.
For more information, visit www.verizonbusiness.com

SOURCE Verizon Business
CONTACT:
Jo Perrin, Verizon Business, +44-770-252-5868,
jo.perrin@verizonbusiness.com
Company News On-Call: http://www.prnewswire.com/comp618232.html
Web site: http://www.verizon.com
http://www.verizonbusiness.com

IntexyS unveils high speed parallel optical engines

IntexyS Unveils High Speed Parallel Optical Engines Powered by Green Friendly Electronics

Toulouse, France and Santa Clara, California (ANTARA News/PRNewswire-AsiaNet) - Intexys

Photonics introduces its family of Optical Engines for parallel optics applications and more particularly for the Optical Active Cable emerging market.

The Optical Engine Family consists of a (4+4) x5Gbit/s Infiniband compliant engine and a QSFP version just released. The family will also include a (4+4) x10Gbit/s engine in March with a 12x10Gbs engine in late 2008.

The engines are manufactured using the Intexys patented "Full-Flip-Chip" concept which enables integration of electronics and optics. The platform achieves high signal integrity and low crosstalk, fine pitch and self-alignment properties leads to high manufacturability and reliability.

The 10Gbit/s products incorporate a low power chip set which allows for the lowest power consumption available in the market and is a true green enabling product family.

"We have introduced a unique parallel optical engine that leaves no compromise on signal integrity and optical alignment. The full flip-chip process is a deterministic approach that changes the rules of optical packaging," says Regis Hamelin, CTO and co-founder of Intexys.

"This development of low power optical engines responds to the demand of the industry for green friendly products for future deployment into multiple applications. We are very proud to be a part of the solution to a major industry initiative," says Terry Thomas, VP of Sales and Marketing.

About Intexys Photonics

Founded in 2002, IntexyS Photonics designs, manufactures and markets highly integrated optical sub-assemblies and modules for high speed applications based on its well patented and industrial proven flip chip hybridization technology.

The company provides multi-standard compliant transmitter and receiver solutions for serial and parallel optical interconnects. Headquartered in Toulouse, France, Intexys
Photonics has Sales and Engineering offices in Santa Clara Ca, USA.

SOURCE: Intexys Photonics
CONTACT:
Terry Thomas of Intexys Photonics, +1-408-492-1629, cell, +1-408-646-7770, tthomas@intexysphotonics.com
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20070905AQW066LOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk: photodesk@prnewswire.com
Web site: http://www.intexysphotonics.com

Perfect timing for Australian anti-money laundering specialist

In Light of Local Legislative AML Developments, Timing Proves Perfect for Formation of Australasian Chapter of Anti-Money Laundering Professionals

Sydney (ANTARA News/PRNewswire-AsiaNet) - The Association of Certified Anti-Money Laundering Specialists (ACAMS) recently announced the formation of the ACAMS Australasian Chapter.

Made up of members within Australia, New Zealand and the Pacific Region, the chapter provides a forum for the professional development and networking of its members who come from a wide range of industry areas involved in the anti-money laundering (AML) field. The Australasian Chapter Board, as well, has been formed from a range of professionals within the AML field experienced across the Australasian and other jurisdictional legislative AML regimes.

"With recent legislative developments within Australia and forthcoming New Zealand legislation, this is a perfect time for the formation of an Australasian Chapter," said Mr Neil Jeans, Head of Group AML, National Australia Bank and Co-Chairman of the Australasian Chapter.

"In addition to providing a locally based forum for the members, the Chapter will develop a local knowledge-based module for CAMS certification in the near future."

ACAMS, a professional association formed in 2002 with 8,000 members in more than 104 countries, also provides a certification program for the CAMS (Certified Anti-Money Laundering Specialist) designation.

The CAMS designation is awarded to professionals in the AML field who are successful in completing a rigorous examination of their knowledge and aptitude in regard to AML detection and enforcement and is maintained by continuing education and professional development.

"ACAMS sets the standards globally for AML professionals," said Jeans.
"This is a tremendous opportunity for current and potential members to be aligned to a local arm of ACAMS where our focus, whilst still aligned to global standards, will be on local legislative requirements and issues. We are encouraging all professionals within the AML field to become active in this Chapter going forward."

Mr Gregory Calpakis, CAMS, Executive Director of ACAMS, continued, "ACAMS has been heavily involved in an ongoing consultation process with firstly the local members and subsequently the Board in the formation of the Australasian Chapter and view it as a key body in the region for expanding the professional knowledge of our members concerning money laundering and terrorist financing, a growing problem which crosses national and geographical borders."

The Australasian Chapter held its inaugural event in Sydney on Monday 18 February. This successful event was fully booked and attended by a wide-range of AML professionals and will be followed by additional events during the year; the events will be scheduled in both Sydney and Melbourne, for members and non-members, as part of the ACAMS continuing professional development program.

About the Association of Certified Anti-Money Laundering Specialists ACAMS is an international membership organization dedicated to enhancing the knowledge and skills of AML professionals around the globe. It serves as a uniquely valuable resource for more than 8,000 members in 104 countries, promoting year-round support to develop and sharpen the skills required for superior job performance and career advancement. Its CAMS certification is the most widely recognized AML certification among compliance professionals worldwide.

To obtain further information on the Australasian Chapter or ACAMS membership please contact Saida Aliyy at sAliyy@acams.org or visit the ACAMS website at www.acams.org

SOURCE: The Association of Certified Anti-Money Laundering Specialists
CONTACT:
Saida Aliyy of The Association of Certified Anti-Money Laundering Specialists, +1-786-871-3055,
sAliyy@acams.org
Web site: http://www.acams.org

Reese Witherspoon, Suze Orman speak at Global Summit

Reese Witherspoon & Suze Orman Speak at Global Summit for a Better Tomorrow in Celebration of International Women's Day

New York (ANTARA News/PRNewswire-AsiaNet) - Avon and UNIFEM Announce Partnership to End Violence against Women and Launch of the Women's Empowerment Bracelet

WHAT: The Global Summit for a Better Tomorrow -- the keystone in a series of Avon initiatives to raise awareness of International Women's Day -- takes place at the United Nations on Tuesday, March 4th.

The Summit is held together with the United Nations Development Fund for Women (UNIFEM), in celebration of International Women's Day, which will be recognized globally on March 8, 2008. It is a holiday whose history can be traced back 150 years and is celebrated in countries all over the world.

At a UN press conference prior to the Summit, Avon and UNIFEM will announce a new public-private partnership that represents the largest corporate one-year grant made to the UN Trust Fund to End Violence against Women.

MORE: Avon Global Ambassador Reese Witherspoon is unveiling the company's first global fundraising product, the Women's Empowerment Bracelet. The bracelet will sell for $3 each and all net profits will be donated to the Avon Empowerment Fund.

In 2008, the Avon Foundation will match the first $500,000 in bracelet sales for a total donation of $1 million to the UN Trust Fund to End Violence against Women. These resources will bolster critical work to prevent and reduce the prevalence of violence against women. Starting March 4, consumers can purchase the bracelets by going online at http://www.avon.com.

B-ROLL: Interviews with Reese Witherspoon, Suze Orman, Andrea Jung (Avon Products, Inc. Chairman and CEO) and Joanne Sandler (UNIFEM Executive Director a.i.), Reese Witherspoon Empowerment Bracelet announcement, Andrea Jung announcement of the Empowerment Fund, and additional highlights.

** Downloadable Video, Pictures & Text Available at http://dogmatic.com/MNR/AvonGlobalSummit

SATELLITE INFORMATION:
EUROPE
Date: 5th March 2008
Time: 0930-1000 GMT (9:30AM LONDON LOCAL)
Satellite: New Skies 7 (KU) Dig
Transponder: ENV8/EUH8/Ch 5
Uplink Frequency: 14474.5 (V)
Downlink Frequency: 11684.5 (H)
Symbol Rate: 6.62
FEC 3/4
Color: PAL
Trouble#: +001.404.638.2000 (Up South) or
+001.646.336.7977
ASIA/PACIFIC
Date: 5th March 2008
Time: 0930-1000 GMT (6:30PM TOKYO LOCAL)
Satellite: IS 2 (C) Dig
Transponder: 04-Ch C
Uplink Frequency: 6007 (H)
Downlink Frequency: 3782 (H)
Symbol Rate: 6.62
FEC: 3/4
Color: PAL
Trouble#: +001.800.922.4424 (Steele Valley) or
+001.646.336.7977
Press Contact: Elana Gichon; 310-450-3884;
elana@dogmatic.com

SOURCE: Avon Products, Inc.
Web site: http://www.avon.com

comScore releases top Japan web site rankings for January 2008

Education, Career, Automotive and Real Estate Sites See Gains to Start the New Year

Tokyo (ANTARA News/PRNewswire-AsiaNet) - comScore, Inc. (Nasdaq: SCOR), a leader in

measuring the digital world, today released its January 2008 rankings of the largest and fastest-growing Internet properties and site categories in Japan, based on data from the comScore World Metrix audience measurement service.

January saw increased visitation to education, career, automotive and real estate sites as many people in Japan focused their Internet activity on planning for the New Year.

Several news sites, including J-Cast.com, Sponichi.com, and Jiji.com, saw significant gains in January, with elections in Osaka, the Sumo wrestling tournament, and the Chinese food scandal being major topics in the news.

"The New Year marks a time when the people of Japan begin planning and looking ahead, especially to the beginning of the new school and job year in April," said Maru Sato, Managing Director of comScore Japan. "Real estate sites also saw gains as visitors sought housing information for both buying and selling."

Top Gaining Site Categories for January 2008 Top Gaining Site Categories by Number of Unique Japanese Visitors January 2008 vs. December 2007

Age 15+ Home and Work Locations*

Source: comScore World Metrix

Total Unique Visitors (000)
Dec-2007
Jan-2008
%

Change Total Internet : Total Audience
54,348
54,544
0
Training and Education
1,791
2,640
47
Real Estate
3,596
5,229
45
Business/Finance - News/Research
7,886
10,300
31
Automotive - Manufacturer
5,668
7,365
30
Career Resources
3,739
4,825
29

* Excludes traffic from public computers such as Internet cafes or access from mobile phones or PDAs.

Top Gaining Properties for January 2008 Top 10 Gaining Properties by Number of Japanese Unique Visitors* January 2008 vs. December 2007

Age 15+ Home and Work Locations**
Source: comScore World Metrix

Property
Total Unique Visitors (000)
Dec-2007
Jan-2008
% Change Total Internet : Total Audience
54,348
54,544
0
J-CAST.COM
1,470
2,678
82
SPONICHI.CO.JP
2,340
3,870
65
JIJI.COM
2,741
3,497
28
FRESHEYE.COM
3,068
3,810
24
YOMIURI.CO.JP
4,561
5,490
20
Mizuho Financial Group
2,496
2,987
20
TV-ASAHI.CO.JP
2,499
2,937
18
NIKKEI.CO.JP
2,777
3,219
16
AMEBLO.JP
12,645
14,072
11
GYAO.JP
5,790
6,408
11

* Ranking based on the top 100 Japanese properties in January 2008.

** Excludes traffic from public computers such as Internet cafes or access from mobile phones or PDAs.

Top 25 Properties for January 2008 Top 25 Properties by Number of Japanese Unique Visitors*
January 2008 vs. December 2007

Age 15+ Home and Work Locations**
Source: comScore World Metrix

Total

Unique Jan-08
Dec-07

Visitors

(000) Rank
Rank
Property
Jan-08 N/A
N/A
Total Internet : Total Audience
54,544 1
1
Yahoo! Sites
42,964 2
2
Google Sites
32,966 3
4
Rakuten Inc
29,921 4
3
Microsoft Sites
29,371 5
5
NTT Group
27,076 6
6
FC2 inc.
27,035 7
7
Nifty Corporation
23,125 8
9
Wikipedia Sites
22,260 9
8
Livedoor
22,109 10
10
GMO Internet Group
20,028 11
11
Amazon Sites
19,101 12
13
NEC Corporation
16,147 13
12
Sakura Internet
15,987 14
15
Apple Inc.
15,633 15
14
Sony Online
15,609 16
16
Excite Japan
14,588 17
17
AMEBLO.JP
14,072 18
N/A*** Hatena
13,080 19
N/A*** KDDI Corporation
12,450 20
18
MIXI, Inc.
12,319 21
19
SEESAA.NET
12,007 22
22
TRACKWORD.NET
10,730 23
20
JWORD.JP
10,678 24
21
IIJ4U.OR.JP
10,094 25
23
NICOVIDEO.JP
9,939 *

Ranking based on the top 100 Japanese properties in January 2008.

** Excludes traffic from public computers such as Internet cafes or access from mobile phones or PDAs.

*** New properties based on January 2008 data; based on aggregations of previously existing entities.

About comScore comScore, Inc. (Nasdaq: SCOR) is a global leader in measuring the digital world. For more information, please visit http://www.comscore.com/boilerplate

SOURCE comScore, Inc.
CONTACT:
Maru Sato of comScore Japan K.K., +81-3-5789-5555, hsato@comscore.com
Photo: http://www.newscom.com/cgi-bin/prnh/20080115COMSCORELOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
Web site: http://www.comscore.com

Micrel previews industry`s hottest new power solutions at IIC China

Chengdu (ANTARA News/PRNewswire-AsiaNet) - Micrel Inc., (Nasdaq: MCRL), an industry leader in IC analog, high bandwidth and Ethernet

solutions, today announced that it would be previewing the industry's newest and most innovative power analog IC solutions at the 13th Annual International IC-China Conference & Exhibition.

The show will be held in four locations this year: Chengdu (Feb. 28-29); Shenzhen (March 3-4); Beijing (March 6-7); and Shanghai (March 10-11), China.

Micrel will also participate in the IIC Power Management and Automotive Electronics Vendor Seminars with the schedule detailed as follows . Power Management Vendor Seminars: Chengdu, Feb. 28, 13:30-14:20 p.m.; Shenzhen, March 3, 13:30-14:20 p.m.; Beijing: March 6, 13:30-14:20 p.m.; and Shanghai, March 10, 13:30-14:20 p.m. Automotive Electronics Vendor Seminars: Chengdu, Feb. 28, 15:40-16:30 p.m.; and Shenzhen, March 4, 14:40-15:30 p.m.

Included in the preview will be a fully-integrated 4A synchronous buck regulator, the MIC22400 for 3V and 5V supply rails. With operating frequency programmable from 800KHz to 4 MHz, the IC features built-in sequencing, tracking and ramp control, enabling all power-up sequencing and tracking protocols.

Targeted at the communications, computing peripherals, and high- end consumer markets, the solution is ideal for servers routers, HD DVD recorders, wireless base stations, FPGAs, DSPs, and low voltage ASICs, as well as other high power density applications.

The Company will also preview the MICRF218 the world's first programmable receiver featuring jam avoidance. The MICRF218, which is part of Micrel's QwikRadio(R) family, is targeted at garage door openers and tire pressure monitoring systems. It is the world's first integrated ASK/OOK receiver with selectable IF bandwidth for 300 to 450 MHz operation.

Finally, Micrel will also showcase the MIC94064/5, a series of high-side load switches that extend Micrel's industry-leading MIC9406 x family of high-side load switch products. The MIC9406 x family now covers a wide range of battery-powered consumer and industrial applications that require a variety of turn-on characteristics, including portable computers, cell phones, and personal media devices.

"Micrel's breadth of analog products now includes more than more than 1,500 solutions including Low Noise Regulators (LDOs), Switchers, Switches (USB, High Side, Cable), Hot Swap Controllers, Power Management, MOSFET Drivers, Voltage References, and Power Supervisors," noted Andrew Cowell, Micrel's vice president of marketing for analog products.

"These new devices, from the world's first programmable receiver featuring jam avoidance, to a the smallest fully-integrated 4A synchronous buck regulator for 3V and 5V supply rails, demonstrate Micrel's on-going commitment to providing China with the most innovative and advanced ICs on the market today."

About Micrel, Inc.

Micrel Inc., is a leading global manufacturer of IC solutions for the worldwide analog, Ethernet and high bandwidth markets. The Company's products include advanced mixed-signal, analog and power semiconductors; high performance communication, clock management, Ethernet switch and physical layer transceiver ICs.

Company customers include leading manufacturers of enterprise, consumer, industrial, mobile, telecommunications, automotive, and computer products. Corporation headquarters and state-of-the-art wafer fabrication facilities are located in San Jose, CA, with regional sales and support offices and advanced technology design centers situated throughout the Americas, Europe and Asia. In addition, the Company maintains an extensive network of distributors and reps worldwide.
Web: http://www.micrel.com.

Note:
MLF is a registered trademark of Amkor Technology.
QwikRadio is a registered trademark of Micrel, Inc. The QwikRadio ICs were developed under a development agreement with AIT of Orlando, FL.

SOURCE: Micrel Inc.
CONTACT:
Julieanne DiBene, Marketing Communications, Micrel Inc.,
+1-408-474-1276, Julie.DiBene@Micrel.com
Web site: http://www.micrel.com

Atmel introduces an AVR-based 2.4 GHz wireless evaluation platform

Atmel Introduces an AVR-based 2.4 GHz Wireless Evaluation and Development Platform at $99

San Jose, California (ANTARA News/PRNewswire-AsiaNet) - The kit allows an easy evaluation of short range wireless connectivity with IEEE802.15.4, ZigBee, 6LoWPAN, etc.

Atmel(R) Corporation (Nasdaq: ATML) announced today the availability of the AVR(R) RZ Raven evaluation kit that provides designers a unique ready-to-use development platform in the rapidly growing low power wireless market for the 2.4GHz ISM frequency band available worldwide.

The kit utilizes the AVR picoPower(TM) technology in combination with the superior RF performance offered by the AT86RF230 2.4 GHz ISM transceiver.

The RZ Raven kit comprises two Raven boards, one USB Stick and a selection of firmware application and software that will dramatically reduce time to market for designers considering short range wireless ISM band applications based on IEEE802.15.4(TM), ZigBee(R) or 6LoWPAN.

The Raven board can be used as a multi application wireless node with a LCD graphical user interface. It has two AVR picoPower microcontrollers: an ATmega1284 P that can be used to control RF application stacks, and an ATmega3290 P that controls the display and user interfaces.

The Raven contains a custom LCD display, a 5 position joystick, a microphone and a speaker allowing the evaluation of a variety of user interactions that are appropriate in the target wireless applications.

To support application development the following functionalities are available: graphical user interface, communication ports, ATmega1284 P port pins available on
headers, on-board temperature sensor, voltage sensor, relay driver, boot loader and ISP support for programming.

The USB stick can serve as a PC gateway to the wireless network, or as the hardware platform for wireless protocol analyzer. It is based on the AT90USB1287 AVR microcontroller and the AT86RF230 transceiver.

The firmware provided includes low level drivers and application stacks enabling simple point to point communication, IEEE 802.15.4 compliant solutions, and more complex applications based on ZigBee and 6LoWPAN. Updated source code, libraries and documentation for the applications are available from the Atmel web site. PC software is also provided, including a demo and a management suite for setup, configuration and management of wireless networks.

Key features include wireless protocol analyzer and Over-The-Air upgrade (OTA).
"Customers selecting the AVR Wireless platform get a flexible solution with a wide selection of microcontrollers tailored for any wireless application," said Magnus Pedersen, Director of AVR Product Marketing.

"Combining the superior RF performance and the extremely low power consumption of picoPower technology, Atmel provides an ideal platform for the rapidly growing market of low power wireless devices demanding years of life on a single battery."

The AT86RF230 offers industry best RF performance with a link budget of 104 dB and gives up to 3 times the range of competitor radios. This results in an outdoor range of up to 700 m with the high gain PCB antenna used on the Raven board. Current consumption in active mode is only 15 mA and down to 20 nA in sleep mode.

AVR picoPower devices consume as little as 340 uA in active mode at 1.8V running from the internal RC oscillator at 1 MHz. In power-save mode it is 500 nA with a real time counter running, and 100 nA in power-down mode. picoPower AVRs are pin-, performance-, and code-compatible with existing AVR microcontrollers giving designers flexible hardware options for small, medium sized and complex wireless networks.

The Raven board and the USB Stick holds FCC and ETSI certification.
Availability and Pricing The new kit is available now at a resale price of US$99. Ordering code is: ATAVRRZRAVEN.

About Atmel

Atmel is a worldwide leader in the design and manufacture of microcontrollers, advanced logic, mixed-signal, nonvolatile memory and radio frequency (RF) components. Leveraging one of the industry's broadest intellectual property (IP) technology portfolios, Atmel is able to provide the electronics industry with complete system solutions focused on consumer, industrial, security, communications, computing and automotive markets.

(C) 2008 Atmel Corporation. All Rights Reserved. Atmel(R), logo and combinations thereof, AVR(R) and others, are registered trademarks, picoPower(TM) and others are trademarks of Atmel Corporation or its subsidiaries. Other terms and product names may be trademarks of others.

Information: AVR RZ Raven information can be retrieved at: http://www.atmel.com/dyn/products/tools_card.asp?tool_id=4291

Product information on Atmel's AVR can be retrieved at http://www.atmel.com/avr

Press Contacts:
Philippe Faure, Marketing Communications Director --
Microcontrollers Tel: +33 2 40 18 18 87,
Email: philippe.faure@atmel.com
Helen Perlegos, Public Relations
Tel: (+1) 408 487-2963,
Email: hperlegos@atmel.com
SOURCE: Atmel Corporation
CONTACT: Philippe Faure, Marketing Communications Director
-- Microcontrollers, +33 2 40 18 18 87,
philippe.faure@atmel.com,
or Helen Perlegos, Public Relations, +1-408-487-2963,
hperlegos@atmel.com, both of Atmel Corporation
Web site: http://www.atmel.com

Germany`s renewable energies industry provides advantages

Washington (ANTARA News/PRNewswire-AsiaNet) - With oil prices exceeding US$100 a barrel, the United States, and the world, is being forced to recognize that fossil fuels may not only be damaging the environment, but also losing their competitive edge regarding price.

Germany is pioneering solutions to this problem. It has demonstrated that renewable energies can play an important role in a sustainable industrial policy -- providing jobs, returns to investors, and carbon emission reductions.

Results from Germany and how to benefit from them will be presented to investors at WIREC 2008, the Washington International Renewable Energy Congress from March 4-6.

Smart legislation has helped make Germany a renewable energies leader. Its Renewable Energy Sources Act (EEG in German) states that owners of renewable energies systems, such as solar panels, receive a "feed-in tariff" when energy from their systems is sold back to the local utility.

This price is guaranteed for twenty years and, depending on the type of energy and system, can be twice the price paid for energy by private households, making it profitable to produce renewable energy.

Germany wants to be the world leader in all renewable energies by 2020.
This will mean a worldwide market share of over 20 per cent, EUR20 billion in domestic investments, and over EUR80 billion in exports.

Furthermore, networks of research institutes and universities work with industry to develop new technologies.
For example, the Fraunhofer Institute in Freiburg, Germany is a leading location for the study of photovoltaic technologies.
The German government has pledged EUR15 billion through 2009 to aid advanced R&D projects.

Germany's favorable legal regime, strong workforce, and network of scientific experts all contribute to the renewable energy industry's impressive statistics: EUR23 billion in revenue in 2006 plus EUR6 billion in exports and EUR9 billion in domestic investments.

Many American firms are taking advantage of Germany's leading position.
General Electric, First Solar, and Nanosolar have all made major new investments in Germany within the past two years.

Invest in Germany is the inward investment promotion agency of the Federal Republic of Germany. It provides investors with comprehensive support from site selection to the implementation of investment decisions. Its booth can be found in the German
Pavilion at WIREC 2008 at the Washington Convention Center.

Media Contact:
Eva Henkel, Invest in Germany,
Phone: +49-30-200099-173,
Fax: +49-30-200099-111,
Email: henkel@invest-in-germany.com
http://www.invest-in-germany.com
SOURCE: Invest in Germany
CONTACT: Eva Henkel of Invest in Germany, +49-30-200099-173,
+49-30-200099-111 Fax, henkel@invest-in-germany.com
Web site: http://www.invest-in-germany.com

ROBODOC emerges as a Curexo Technology Company at upcoming Con

ROBODOC(R) Emerges as a Curexo Technology Company at Upcoming Orthopaedic Surgeons Conference in San Francisco

Sacramento, California (ANTARA News/PRNewswire-AsiaNet) - ROBODOC, a Curexo Technology Company, and newly formed division of Curexo, Inc.,

announced today that they will be exhibiting at the upcoming American Association of Orthopaedic Surgeons Annual Conference being held at the Moscone Center in San Francisco, March 5th through the 7th; Hall D, Booth #4470.

"Because the ROBODOC Product brand has a strong worldwide recognition, Curexo Inc. has decided to name the company ROBODOC, a Curexo Technology Company," said Dr. Ramesh Trivedi, President and CEO.

"We are looking forward to attending the AAOS meeting in San Francisco to present the only fully automated Robotics technology to the US orthopaedic community even though, it has been available for many years to the surgeons throughout the world."

"Combining our pioneering work with many years of experience of routinely performing joint replacement surgeries overseas and the strong support of our new partner, Curexo Inc., strongly positions us to offer a unique solution for the current and future challenges in orthopaedic surgery. Together with our partner Curexo, Inc. we have developed strong technical and marketing initiatives for the future, and are prepared to move forward into the US Market," added Dr. Trivedi.

About ROBODOC

ROBODOC, develops, manufacturers, and markets a fully automated surgical robotic system for orthopaedic surgery. The system includes two components; ORTHODOC, a computer workstation equipped with proprietary software for preoperative surgical planning, and ROBODOC, a computer-controlled surgical robot for use in hip and knee replacement as well as other orthopaedic surgeries.

ROBODOC made medical history in 1992 by assisting in a Total Hip Arthroplasty (THA) procedure. Since that time, the ROBODOC system has been used in over 20,000 surgical procedures to assist the surgeons around the world. The ROBODOC Surgical Assistance System is currently in its final stage of review and clearance by the FDA.

ROBODOC(R) and ORTHODOC(R) are registered trade marks of Curexo Technology Corporation 1433 N. Market Blvd., Suite 1, Sacramento, CA 95834 http://www.robodoc.com

Contact:
Dr. R.C. Trivedi
President & CEO ROBODOC(R) A Curexo Technology Company 916 285 9943 x 527 or
Ms. Sheila Shah
Marketing Communications ROBODOC(R) A Curexo Technology Company 916 285 9943 X 510
press@robodoc.com
SOURCE ROBODOC
CONTACT: Dr. R.C. Trivedi, President & CEO, ext. 527,
or Ms. Sheila Shah, Marketing Communications, ext. 510, both
of ROBODOC, +1-916-285-9943, press@robodoc.com
Web site: http://www.robodoc.com

Luminary Micro adds new parts, packages, and temperature grades

Luminary Micro Adds New Parts, Packages, and Temperature Grades to the Largest Selection of ARM-based Microcontrollers

Austin, Texas (ANTARA News/PRNewswire-AsiaNet) - Luminary Micro (www.LuminaryMicro.com), creators of the award-winning Stellaris(R) family of ARM(R)

Cortex(TM)-M3-based microcontrollers (MCUs), today announced the immediate availability of nineteen new Stellaris family members, providing cost-effective entry points and precise motion control support.

Additionally, Luminary Micro extends the capability and reach of the entire Stellaris family by announcing a new small BGA (ball-grid array) package option with a space-saving 10mm by 10mm footprint and a new extended temperature option with a -40 to 105 degrees Celsius operating temperature range.

"As ARM's lead partner in the development of the Cortex-M3 core, Luminary Micro was the first company to bring the ARM Cortex-M3 to market. With today's announcement, we have now brought 104 Stellaris ARM Cortex-M3-based microcontrollers to market in just two years," said Jean Anne Booth, Chief Marketing Officer of Luminary Micro.

"The addition of extended temperature range and small BGA packages opens up even more opportunities for customers to add capabilities to their products that were previously out of reach."

60 per cent Footprint Reduction in 108-BGA Package
The new 108-BGA packages provide up to a 60 per cent smaller footprint than current Stellaris-family devices available in a 100-pin LQFP package. This small 10mm by 10mm package enables the use of fully-featured Stellaris microcontrollers in designs where board space is limited, such as a motor with integrated control electronics.

19 New MCUs Extend the World's Largest Selection of ARM-based MCUs
Eighteen of the new Stellaris microcontrollers provide capable, cost-efficient entries into the product family. These include six LM3S300/600/800 low pin count real-time MCU series family members, four LM3S1000 high pin count real-time MCU series family members, four LM3S2000 CAN-enabled MCU series family members, and four LM3S6000 Ethernet-enabled MCU series members.

These entry-level MCUs provide single cycle on-chip flash ranging from 16KB to 256KB, single cycle on-chip SRAM ranging from 4KB to 64KB, and include I2Cs, SPIs, UARTs, up to four flexible 32-bit timers, and up to eight channels of analog-to-digital conversion.

Also announced today is the LM3S8971, which provides a new option for precision motor control, with six motion-control capable PWMs, a CAN 2.0 A/B controller and an integrated 10/100 Ethernet MAC / PHY. The recently announced Brushless DC Motor Control Reference Design Kit (RDK-BLDC) features the new LM3S8971 and includes four-quadrant motor control for three-phase brushless DC motors rated at up to 36 V and 60,000 RPM.

New Extended Temperature Option Extends Operating Range
Rounding out the capabilities announced today is a new extended temperature operating range, adding an option for -40 to 105 degree Celsius extended temperature operating range.
Both the new extended temperature grade and current industrial temperature grade (-40 to 85 degree Celsius) options are available across the entire Stellaris family of microcontrollers.

Stellaris Features the Cortex-M3 Core The ARM Cortex-M3 processor, the microcontroller member of the ARM Cortex processor family, is at the heart of all Stellaris microcontrollers. Designed for serious microcontroller applications, the Cortex-M3 core features highly deterministic, fast interrupt processing - as low as six cycles and never more than twelve cycles.

At the heart of the Cortex-M3 processor is an advanced 3-stage pipeline core, based on the Harvard architecture, incorporating features such as branch speculation, single cycle multiply and hardware divide to deliver exceptional performance.

Cortex-M3 implements the new Thumb(R)-2 mixed 16-/32-bit instruction set architecture without mode switching, helping it to be 70 per cent more efficient per MHz than an ARM7TDMI-S(R) processor executing Thumb instructions, and 35 per cent more efficient than the ARM7TDMI-S processor executing ARM instructions, for the Dhrystone benchmark.

The Stellaris microcontroller family features a fully integrated 10/100 Ethernet, up to three integrated Bosch CAN 2.0 A/B controllers, three UARTs, two I2Cs, and two synchronous serial interfaces (SSI).

Stellaris Ethernet-enabled devices combine both the Media Access Control (MAC) and Physical (PHY) layers, marking the first time that integrated connectivity is available with an ARM Cortex-M3 MCU and the only integrated 10/100 Ethernet MAC and PHY available in an ARM architecture MCU.

The integrated Ethernet features automatic MDI/MDI-X cross-over detection, and several Ethernet-enabled Stellaris microcontrollers also include hardware-assisted support for synchronized industrial networks utilizing the IEEE 1588Precision Time Protocol (PTP).

Pricing and Availability The new Stellaris MCUs are available now through Luminary Micro's global sales channel (www.LuminaryMicro.com/sales) and online (www.LuminaryMicro.comproducts/) starting at a suggested price of USD 1.75 (10,000
unit quantity).

About Luminary Micro and Stellaris

Luminary Micro, Inc. designs, markets and sells ARM Cortex-M3-based microcontrollers (MCUs). Austin, Texas-based Luminary Micro is the lead partner for the Cortex-M3 processor, delivering the world's first silicon implementation of the Cortex-M3 processor.

Developed for use in embedded and industrial applications, Luminary Micro's introduction of the award-winning Stellaris(R) family of products provides 32-bit performance for the same price as current 8- and 16-bit microcontroller designs. With
entry-level pricing at $1.00 for an ARM technology-based MCU, Luminary Micro's Stellaris product line allows for standardization that eliminates future architectural upgrades or software tools changes.

Stellaris and the Luminary Micro logo are registered trademarks of Luminary Micro, Inc. or its subsidiaries in the United States and other countries. All other brands or product names are the property of their respective holders.

Luminary Micro Company Contact:
Jean Anne Booth / CMO / +1.512.917.3088 mobile / +1.512.279.8801
office / JeanAnne.Booth@LuminaryMicro.com
SOURCE: Luminary Micro, Inc.
CONTACT: Jean Anne Booth, CMO, Luminary Micro, Inc.,
+1-512-279-8801, mobile, +1-512-917-3088,
JeanAnne.Booth@LuminaryMicro.com
Web site: http://www.luminarymicro.com

DARA BioSciences, Inc. announces appointment of new director to board

Raleigh, North Carolina (ANTARA

News/PRNewswire-AsiaNet) - DARA BioSciences(TM) (Nasdaq: DARA) announced today the appointment of Haywood D. Cochrane, Jr. to the Board of Directors.

Mr Cochrane was appointed to fill a Board vacancy and will serve on the Company's Audit and Compensation Committees. The appointment was effective February 21, 2008.

In making the announcement DARA's Board Chairman, Richard Franco, Sr., commented, "We are pleased that Haywood has joined us as a Director. His vast knowledge and successful experience in the healthcare industry will further strengthen DARA's already skilled Board."

Mr Cochrane is currently Vice Chairman and a Director of I-trax, Inc.

(Amex: DMX), a publicly traded, total population health management and productivity company. Mr Cochrane has previously served as a Director of seven other publicly-traded companies.

About DARA BioSciences, Inc.

DARA BioSciences(TM), Inc. ("DARA") is a Raleigh, North Carolina-based development-stage pharmaceutical company that acquires promising therapeutic molecules and medical technologies directly or through investment in established companies.

DARA focuses its therapeutic development efforts on small molecules from late preclinical development through phase 2 clinical trials. DARA is developing a portfolio of therapeutic candidates for neuropathic pain, metabolic diseases including type 2 diabetes, dyslipidemia and dermatological disorders. DARA has licensed promising drug development candidates from Kirin Pharmaceuticals of Japan, Bayer Pharmaceuticals Corporation, Massachusetts General Hospital and Nuada LLC.

For more information please contact the Company at 919-872-5578 or visit our web site at www.darabio.com

All statements in this news release that are not historical are forward-looking statements within the meaning of the Securities Exchange Act of 1934 as amended. Such forward-looking statements are subject to factors that could cause actual results to differ materially for DARA from those projected.

Those factors include risks and uncertainties relating to the company's ability to develop and bring new products to market as anticipated, the current regulatory environment in which the company develops and sells its products, the market acceptance of those products, dependence on partner, successful performance under collaborative and other commercial agreements, competition, the strength of DARA's intellectual property, the intellectual property of others and other risk factors identified in the documents DARA has filed, or will file, with the Securities and Exchange Commission. Copies of DARA's filings with the SEC may be obtained from the SEC Internet site at http://www.sec.gov.

DARA expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DARA's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. DARA BioSciences and the DARA logo are trademarks of DARA BioSciences, Inc.

SOURCE: DARA BioSciences, Inc.
CONTACT: John C. Thomas, Jr., Chief Financial Officer,
+1-919-872-5578, or Lynn H. Morris, Sr. Manager, Investor
Relations & Corporate Operations, +1-919-872-5578, both of DARA
BioSciences, Inc.
Web site: http://www.darabio.com

Nido Thrilled With the Results From Galoc 3

Perth (ANTARA News/PRNewswire-AsiaNet) - Nido Petroleum Ltd (Nido) is pleased to announce that the Galoc 3 horizontal production well flowed oil to the surface unassisted at a maximum rate of 5,397 barrels per day during clean up flow testing on 20 and 21 February 2008.

The purpose of the Galoc 3 clean up and oil flow to surface was to confirm the integrity of the well and installed completion equipment as well as to ascertain the wells ability to flow.

Pressure, temperature and flow rate data were recorded on surface and on subsurface gauges located down-hole, close to the reservoir. Oil samples were also collected and will be sent to a specialist laboratory for assay and PVT analysis.

This data will provide confirmation of; initial reservoir conditions, initial fluid properties, reservoir formation properties and the potential productivity of the well to the FPSO.

Nido's preliminary analysis of the data overnight confirms the expected maximum flow capacity of the well is consistent with its range of predevelopment estimates.

This will be confirmed by a full and detailed testing program to be conducted once the well has been brought into production service through the FPSO.

During normal production operations, production from Galoc 3 to the FPSO will likely be controlled at rates below its maximum capacity to manage the reservoir effectively to maximise total recovered oil volumes throughout the life of the field. In addition, the FPSO processing capacity of the combined flow of both wells is limited to a maximum of 25,000 bopd.

Nido's Deputy Managing Director, Ms Joanne Williams, said "We are excited to reach this important stage in the Galoc development project. The Galoc-3 well has flowed as designed and is now ready for production service. Nido congratulates the Operator, the Galoc Production Company, on successfully flowing Galoc oil to surface for the first time since 1988, 20 years ago. We eagerly await the results from Galoc 4 in the coming week."

Preparations will now commence for the installation of the Galoc 4 sub-sea tree followed by similar testing of that well. The drill ship Energy Searcher will then be demobilised to Singapore prior to its release. The installation of the mooring and riser system and hook-up to the FPSO will follow over the coming weeks.

"The successful testing of Galoc 3 marks a major milestone for Nido and most importantly for the country of The Philippines" says Chairman of the Board, David Whitby.

Nido is preparing for commercial production from Galoc in April 2008.

For more information please visit www.nido.com.au.

For Further Information contact:
Sascha Stone PR Advisor Nido Petroleum Limited
Tel: +61 (08) 9473 0546/ Mob: +61 417
174 072 Fax: +61 (08) 9473 0576
Email: pmswa@ozemail.com.au
SOURCE: Nido Petroleum

Abbott, Genentech and WEHI collaborate to research and develop drugs

Melbourne (ANTARA News/PRNewswire-AsiaNet) - The Walter and Eliza Hall Institute of Medical Research (WEHI) announced today that Abbott, a global, broad-based, healthcare company, Genentech, a leading biotechnology company based in South San Francisco and WEHI have joined in a tripartite research collaboration to discover new anti-cancer drugs.

"This exciting three party research collaboration among world leaders in this field may increase the chance of translating basic scientific research in apoptosis, the process of programmed cell death, as carried out by our collaborators over recent years, into novel targeted cancer therapeutics" says Dr. Julian Clark, Head of Business Development at WEHI.

"We are excited to collaborate with Abbott and Genentech based on their expertise in apoptosis and strong track records in the development of small molecule drugs. We believe both will be excellent collaborators in bringing forward potential novel cancer therapeutics that target the apoptosis pathway," explains WEHI cancer researcher, Dr. David Huang.

Under the terms of the collaboration the three parties are engaged in a drug discovery research program, with Genentech and Abbott being responsible for the development, manufacturing and commercialization of potential new drugs.

The discovery stage of the collaboration involves an integrated approach engaging research sites in South San Francisco, the Chicago area and Melbourne.

Financial terms of the collaboration will not be disclosed.

WEHI's director, Professor Suzanne Cory, emphasizes that "WEHI's first priority is to work to ensure that cancer patients benefit from the results of our fundamental research and all three parties in the collaboration are committed to the discovery and development of improved cancer treatments that enable patients to live longer and healthier lives".

Further information: Dr. Julian Clark, Head Business
Development WEHI: +61-3-9345-2612; jclark@wehi.edu.au
Brad Allan Communications Manager WEHI: +61-3-9345-2345 Mob +61-403036116
SOURCE: Walter & Eliza Hall Institute

Reports of increased survival in bird flu patients taking Tamiflu

Basel, Switzerland, (ANTARA News/PRNewswire-AsiaNet) - Physicians from countries worst-affected by the deadly bird flu (H5N1 influenza virus) have reported an increased survival rate in patients treated with the oral antiviral Tamiflu (oseltamivir).

These data reinforce the World Health Organization (WHO) advisory that Tamiflu is the only antiviral strongly recommended for the treatment of humans infected with the H5N1 virus. The physicians' report was revealed this week at the International Symposium on Respiratory Viral Infections (ISRVI) in Singapore.(1)

According to the WHO the H5N1 virus has already killed 234 people in 12 countries.(2)

Tamiflu is the only antiviral reported to have been used against H5N1 in humans outside the laboratory and actually in the field.

In Indonesia, of the total of 119 H5N1 human cases reported, 22 survived - an 18 percent survival rate overall. Of these, 33 patients received no Tamiflu, all of whom died. Tamiflu was administered to 86 patients with a 26 percent survival rate overall. Time from onset of illness to initiation of treatment appeared to influence survival. Of the 2 patients who received Tamiflu within 24 hours of illness onset both survived. 55 percent survived if given the drug within four days (6/11), and 35 percent survived if given Tamiflu within six days (13 37)(3).

The survival rate of those receiving it later than 6 days after illness onset was 18 percent (9/49).(2)

Recent information on 8 Vietnamese patients infected with H5N1, was also presented. All 8 patients received Tamiflu. However, all 8 patients presented to the hospital later than 5 days after onset of illness. Only 3 of the 8 patients survived reinforcing that treatment benefit is reduced for patients that receive the drug later in the course of illness. (3,4) In 2 patients who were unable to take the drug orally due to the severity of their illness physicians administered the drug by nasogastric tube and found it was well absorbed and there was a reduction in H5N1 virus in these patients.

Susceptibility of circulating H5N1 strains to Tamiflu

These clinical findings are supported by new animal data, also presented at ISRVI, which shows that oseltamivir treatment was effective against H5N1 influenza viruses representing different clades/subclades. However higher doses were required for the more pathogenic H5N1 viruses.(5)

"Multiple factors can affect the susceptibility of antiviral therapy with highly pathogenic H5N1 influenza viruses and it is reassuring that oseltamivir, in mouse models, demonstrates activity even to the most pathogenic circulating strains," comments study author Dr. Elena Govorkova, St. Jude Children's Research Hospital, Memphis, US. "Antiviral drugs are an essential component for the early control of an influenza pandemic."

Data also confirms the low level of resistance reported to date with Tamiflu to H5N1 avian influenza in the field; there are only five cases of published reports of H5N1 resistance or reduced susceptibility to Tamiflu to date.(6,7,8)

Laboratory results have shown 96 percent of H5N1 strains (53 out of 55) tested in the laboratory were sensitive to Tamiflu.(9)

This compares to the around 14 percent of isolates tested this year of the seasonal influenza A H1N1 virus showing resistance to Tamiflu, reported at the conference.(10)

It is important to note that these increased levels of resistance have only been reported spontaneously in this year's H1N1 (Solomon Islands) seasonal strain, and not an avian strain such as H5N1 and not in patients who have been administered Tamiflu.(11)

"Currently, we are seeing that Tamiflu has been used as part of the clinical management of patients infected with H5N1 with only isolated cases of resistance being reported," comments Dr David Reddy, Global Pandemic Task Force Leader at Roche. "This is reassuring for governments that have stockpiled Tamiflu for pandemic use. It is however critical that both Roche and the medical community remain vigilant so that we can understand this mutating virus and be best prepared for defence against a potential pandemic strain."

Roche has undertaken several research initiatives to study the use of Tamiflu against the evolving H5N1 avian influenza virus, including collaborations with the National Institutes of Health (NIH), the Southeast Asia Influenza Clinical Trials Research Network and other research institutions.

Note to editors:

Difference between a pandemic strain of influenza and seasonal influenza

A pandemic strain of influenza is always of the A variety and is a completely new strain to which there will be no immunity whereas a seasonal strain of influenza is one that has previously been circulating, which may have changed slightly (antigenic drift) and to which a level of immunity exists.

About pandemic influenza

An influenza pandemic occurs when a new strain of influenza A virus appears, against which the human population has no immunity resulting in several, simultaneous epidemics worldwide with enormous numbers of deaths and illness. The most severe influenza pandemics to date include: 'Spanish flu' A (H1N1): 1918 caused in excess of 30 million deaths worldwide, 'Asian flu' A (H2N2): 1958 caused 1 million deaths worldwide, 'Hong Kong flu' A (H3N2): 1968 caused 800,000 deaths worldwide in six weeks. The WHO believes that we are as close to the next pandemic as we have been any time in the past 37 years, with two of the three widely-recognised prerequisites for a human pandemic met to date in the avian influenza outbreak in East Asia. Firstly, a new influenza virus strain has emerged (H5N1), and secondly, the virus has spread to humans. The final barrier will be the transmission of the virus from human to human.

About Tamiflu

Tamiflu is designed to be active against all clinically relevant influenza viruses and works by blocking the action of the neuraminidase (NA) enzyme on the surface of the virus. When neuraminidase is inhibited, the spread of the virus to other cells in the body is inhibited. It is licensed for the treatment and prophylaxis of influenza in children aged one year and above and in adults. The most frequently reported adverse events in clinical studies were nausea, vomiting, and diarrhea. Tamiflu is available for the treatment of influenza in more than 80 countries worldwide.

Tamiflu was approved based on studies in seasonal influenza. The magnitude of effect of Tamiflu in treating and preventing novel strains of influenza (such as those that may be involved in a pandemic or associated with avian flu) cannot be predicted. The WHO has recommended that higher doses and longer duration may be required

Roche and Gilead

Tamiflu was invented by Gilead Sciences and licensed to Roche in 1996. Roche and Gilead partnered on clinical development, with Roche leading efforts to produce, register and bring the product to the markets. Under the terms of the companies' agreement, amended in November 2005, Gilead participates with Roche in the consideration of sub-licenses for the pandemic supply of Tamiflu in resource-limited countries. To ensure broader acess to Tamiflu for all patients in need, Gilead has agreed to waive its right to full royalty payments for product sold under these sub-licenses.

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech

company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, a market leader in virology and active in other major therapeutic areas such as autoimmune diseases, inflammation, metabolism and central nervous system.

Additional information
- Roche Health Kiosk, Influenza: www.health-kiosk.ch start_grip.htm
- About Tamiflu: www.roche.com/med_mbtamiflu05e.pdf
- About influenza: www.roche.com/med_mbinfluenza05e.pdf
- WHO: Global influenza programme: www.who.int/csr/disease influenza/en/
- WHO: Avian flu: www.who.int/mediacentre/factsheets avian_influenza/en/

References
(1) Antivirals and therapeutics session, X International symposium on Respiratory Viral infections, Singapore, Sunday 2nd March 2008

(2) World Health Organization. Cumulative Number of Confirmed Human Cases of Avian Influenza A/(H5N1) Reported to WHO. 28 February 2008 http://www.who.int/csr/disease avian_influenza/country/cases_table_2008_02_28/ en/index.html
(3) Sedyaningsih ER. The Indonesian Experience, X International symposium on Respiratory Viral infections, Singapore, Sunday 2nd March 2008

(4) Wertheim HFI. The recent Vietnamese Experience, X International symposium on Respiratory Viral infections, Singapore, Sunday 2nd March 2008
(5) Govorkova E. Influenza Antivirals in H5N1 Disease, Animal Model, X International symposium on Respiratory Viral infections, Singapore, Sunday 2nd March 2008

(6) Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus. Update on Avian Influenza A (H5N1) Virus Infection in Humans. N Engl J Med 358;3

(7) de Jong MD, Thanh TT, Khanh TH, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005;353:2667-72

(8) Saad MD, Boynton BR, Earhart KC, et al. Detection of oseltamivir resistance mutation N294S in humans with influenza A H5N1. In: Program and abstracts of the Options for the Control of Influenza Conference, Toronto, June 17-23, 2007:228. abstract.

(9) Hurt AC. et al. Susceptibility of highly pathogenic (H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Research 73 (2007) 228-231

(10) World Health Organization. Influenza A (H1N1) virus resistance to oseltamivir - Last quarter 2007 to 28 February 2008. 28 February 2008. http://www.who.int/csr/disease/influenza H1N1ResistanceWeb20080228.pdf

(11) World Health Organization. WHO/ECDC frequently asked questions for Oseltamivir Resistance. Last updated 15 February 2008.

SOURCE: Roche
CONTACT: Helen Walicka, International Communications Manager,
+41-(0)-79-263-9701/
Web site: http://www.roche.com /

Digi releases extended-range RF module designed for ZigBee mesh

Minnetonka, Minnesota, (ANTARA News/Xinhua-PRNewswire-AsiaNet) -

Digi International (Nasdaq: DGII) today introduced the XBee-PRO ZNet 2.5, an extended-range RF module designed for ZigBee mesh networking.

The powerful XBee-PRO ZNet 2.5 provides up to 1 mile (1.6 km) RF line-of-sight transmission, significantly increasing the number of applications in which ZigBee mesh networking can be used.

It is the latest addition to Digi's Drop-in Networking product family and is fully compatible with any other XBee ZNet 2.5 Drop-in Networking product, including RF modules, adapters, wall routers and gateways.

"Because of the extended range, ZigBee mesh networking can now be used for applications where there is a greater distance between nodes like automated meter reading, asset management and remote sensor management," said Larry Kraft, senior vice president of global sales and marketing, Digi International.

"The interoperability with Digi Drop-in Networking products and XBee modules also provides customers a tremendous amount of flexibility."

The XBee-PRO ZNet 2.5 provides reliable, wireless data communication over ZigBee networks and satisfies the unique needs of low cost, low-power wireless applications.

It is a fully compatible, pin-swappable extended-range counterpart to the cost optimized XBee ZNet 2.5 which provides up to 400 feet RF line-of-sight transmission.

The XBee-PRO ZNet 2.5 operates on the 2.4 GHz ISM band making it appropriate for use worldwide. It is easy to use and ready to operate out of the box, will be available with four antenna options, has a small form factor and shares the XBee footprint.

XBee RF modules are part of Digi's full line of Drop-in Networking solutions. Drop-in Networking products provide end-to-end connectivity to commercial-grade electronic devices in locations where wired infrastructure does not exist or satisfy customer needs.

The XBee-PRO ZNet 2.5 is available now for USD27.60 in quantities of 1,000.

Development kits are also available for USD339 that include all of the tools necessary to make deployment easy.

For more information about the XBee-PRO ZNet 2.5, visit http://www.digi.com/products/wireless/zigbee-meshxbee-pro-series2-module.jsp .

For more information about Drop-in Networking, visit http:// www.digi.com/products/wirelessdropinnetworking/

About Digi International

Digi International, the leader in device networking for business, develops reliable products and technologies to connect and securely manage local or remote electronic devices over the network or via the web.

Digi offers the highest levels of performance, flexibility and quality, and markets its products through a global network of distributors and resellers, systems integrators and original equipment manufacturers (OEMs).

For more information, visit Digis Web site at http:/www.digi.com, or call +852-2833-1008.

All brand names and product names are trademarks or registered trademarks of their respective companies.

Press Contacts: Hokie Chan Channel Marketing Manager, Asia Pacific
Tel: +852-2235-2206 Email: hokiec@digi.com
SOURCE Digi International Inc.

Meiji University chooses Thomson Scientific`s Century of Science

Meiji is the First Private University in Japan to Have Full Access to Web of Science

Philadelphia and London, (ANTARA News/PRNewswire-AsiaNet) - Thomson Scientific, part of

The Thomson Corporation (NYSE: TOC; TSX: TOC) and leading provider of information solutions to the worldwide research and business communities, today announced that Century of Science(TM) has been purchased by Meiji University in Japan, expanding its subscription to Web of Science earlier this year.

The University's added investment in Century of Science gives students full access to the most important scientific bibliographic and cited reference data covering the period from 1900 to 1944.

"The purchase of Century of Science is right in line with Meiji University's goals to provide access to unsurpassed scientific research information. Backfiles are crucial to research in tracking past developments, pinpointing key turning points and determining the future direction of research," said Mark Garlinghouse, Thomson Scientific's VP and Managing Director, Asia Pacific. "With access to this unparalleled historical research, Meiji University will make great strides toward groundbreaking discoveries."

In January 2008, Meiji University purchased access to Web of Science, a carefully selected and maintained collection of the world's most influential journals across all disciplines. Coverage is truly multidisciplinary with emphasis on quality and superior collection development and can be accessed via the ISI Web of Knowledge, a premier research platform that offers an extensive collection of backfiles to 1945. Launched in January 2005, the Century of Science initiative made available approximately 850,000 articles from more than 200 journals carefully selected from the published research in the first half of the 20th century.

While more than 200 universities throughout the world have Century of Science, Meiji University is the first private university, and the fourth academic institution in Japan to acquire it. Access to this knowledge platform sets the university apart from other mid-sized private institutions and increases the research competitiveness of the students and faculty.

"ISI Web of Science is a very important and useful research tool and it is frequently reputed among researchers. As the first private university in Japan to offer Century of Science, we expect this will have a very large impact on improving our level of research output," said Koki Matsuse, Executive Trustee, Professor of School of Science and Technology, Meiji University.

Meiji University was founded by three young legal professionals to acknowledge, respect and strengthen the individual, and aims to make dramatic advances into the world as the top 21st-century urban university in Japan.

For more information, visit isiwebofknowledge.com.

About Meiji University

Meiji University solidly ranks among the best universities in Japan, currently consisting of eight schools; the Graduate School, made up of 7 departments; independent schools in various disciplines; and the Meiji University Junior High School and Meiji University High School. Meiji University has expanded as one of the prominent private universities of Japan, celebrating its 120th anniversary in 2001. With Rights, Liberty, Independence and Self-government as its guiding principles, Meiji University is committed to fostering human resources who satisfy the requirements "austerity and sturdiness", "creation of new intellect" and "needs of the times". Turning out more than 480,000 graduates into the world to date, it has contributed vastly to the progress of society. The achievements of the university's numerous alumni actively engaged in key roles in various walks of life are highly reputed.

About The Thomson Corporation

The Thomson Corporation (www.thomson.com) is a global leader in providing essential electronic workflow solutions to business and professional customers. With operational headquarters in Stamford, Conn., Thomson provides value-added information, software tools and applications to professionals in the fields of law, tax, accounting, financial services, scientific research and healthcare. The Corporation's common shares are listed on the New York and Toronto stock exchanges (NYSE: TOC; TSX: TOC).

Thomson Scientific is a business of The Thomson Corporation. Its information solutions assist professionals at every stage of research and development-from discovery to analysis to product development and distribution. Thomson Scientific information solutions can be found at scientific.thomson.com.

SOURCE: Thomson Scientific

CONTACT: Susan Besaw,
Thomson Scientific,
+1-215-823-1840,
susan.besaw@thomson.com
Web site: http://www.scientific.thomson.com
http://isiwebofknowledge.com
http://www.thomson.com

Thomson Scientific launches ScienceWatch.com

Free Web Environment Provides Rankings, Trends and Analysis From Around the Scientific Community

Philadephia and London, (ANTARA News/PRNewswire-AsiaNet) - Thomson Scientific, part of The Thomson Corporation (NYSE: TOC; TSX: TOC) and leading

provider of information solutions to the worldwide research and business communities, today announced the launch of ScienceWatch.com, a free, open Web resource for science metrics and analysis.

ScienceWatch.com combines the newest Science Watch newsletter material and regularly updated data, analysis, interviews, and commentary that had been previously found in In-Cites and ESI Special Topics. The website provides the scientific community a convenient location for keeping up with the latest developments in science -- what the leading scientists have to say, how the hottest topics are affecting research and everyday life, where the most significant research is taking place, and much more.

"The database provides an unbiased way to survey the scientific landscape and spot features that are newsworthy and significant, including new topics, new developments, new trends," said Henry Small, chief scientist at Thomson Scientific. "Then we dig deeper and interview the scientists involved. So when you access sciencewatch.com, you're accessing the scientific community and discovering their perspectives and insights."

In addition to the weekly updates, users will be able to see the current issue of Science Watch immediately. Meanwhile, the existing, premium Science Watch/Hot Papers Database subscription package--including the print edition and the accompanying Hot Papers CD with its store of updated, searchable data on thousands of recent, highly cited papers--will still be supplied for current and prospective subscribers.

"Thomson Scientific is the first to provide such a robust Web environment," said Christopher King, editor of Science Watch. "ScienceWatch.com will be a resource to not only the bibliometric community, but anyone remotely connected to any science, research or evaluative field."

About The Thomson Corporation

The Thomson Corporation (www.thomson.com) is a global leader in providing essential electronic workflow solutions to business and professional customers. With operational headquarters in Stamford, Conn., Thomson provides value-added information, software tools and applications to professionals in the fields of law, tax, accounting, financial services, scientific research and healthcare. The Corporation's common shares are listed on the New York and Toronto stock exchanges (NYSE: TOC; TSX: TOC).

Thomson Scientific is a business of The Thomson Corporation. Its information solutions assist professionals at every stage of research and development--from discovery to analysis to product development and distribution. Thomson Scientific information solutions can be found at scientific.thomson.com.

SOURCE Thomson Scientific
CONTACT: Sue Besaw of Thomson Scientific,
+1-215-823-1840,
susan.besaw@thomson.com/
Web site: http://www.scientific.thomson.com
http://www.thomson.com
http://ScienceWatch.com

Heidrick & Struggles up 58.8 percent in Asia Pacific

Sydney, (ANTARA News/Xinhua-PRNewswire-AsiaNet) - Heidrick & Struggles increased its

net revenue by 58.8 per cent in the Asia Pacific region last year, driven by continuing high demand for leadership advisory and executive search services.

Net revenue for APAC was $US78.6 million. Operating income of $US15.9 million increased 20.1 per cent compared with 2006 and the operating margin was 20.3 per cent, compared with 26.8 per cent in 2006 as the firm invested in infrastructure to support its expansion.

Regional managing partner Gerry Davis says that Australia New Zealand, Greater China and Singapore recorded the highest growth rates, with ANZ revenue up 118 per cent on last year, Greater China up 33 per cent, Singapore 72 per cent, India, 29 per cent, Japan 33 per cent and Korea 61 per cent.

Davis says that an aggressive recruiting effort and investment in information technology infrastructure have provided a strong foundation for further regional expansion in 2008.

"Offices have also been expanded and upgraded to cater for the increased headcount. We have opened an office in Bangkok, Thailand to address the significant demand for multi-national and in-country executives," Davis says.

The scale of reach of the Heidrick & Struggles operation in Asia Pacific has caused many corporations to seek access to its "thought leadership", industry sector analysis and research materials, Davis says.

Leadership advisory practice leader Steve Langton says the firms advisory work has helped to increase the number of chief executive and non-executive director roles. "Leadership advice leverages the Heidrick & struggles reputation, brand and capability to support clients in addressing their talent concerns they have in a time of leadership transition." Langton says.

Globally, for the fiscal year ended December 31, Heidrick & Struggles reported consolidated net revenue of $US619.7 million, an increase of 29.5 per cent from $US478.5 million in 2006. The firm expects global revenue to grow by between 5 and 8 per cent in 2008.

About Heidrick & Struggles International, Inc.

Heidrick & Struggles International, Inc. is the worlds premier provider of senior-level executive search and leadership consulting services, including talent management, board building, executive on-boarding and M&A effectiveness.

For more than 50 years, we have focused on quality service and built strong leadership teams through our relationships with clients and individuals worldwide. Today, Heidrick & Struggles leadership experts operate from principal business centers in North America, Latin America, Europe and Asia Pacific.

For more information about Heidrick & Struggles, please visit http://www.heidrick.com

Safe Harbor Statement

This press release contains forward-looking statements. The forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry in which we operate and managements beliefs and assumptions.

Forward-looking statements may be identified by the use of words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "projects," "forecasts," and similar expressions. Forward-looking statements are not guarantees of future performance and involve certain known and unknown risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may differ materially from what is expressed, forecasted or implied in the forward-looking statements. Factors that may affect the outcome of the forward-looking statements include, among other things: our ability to attract and retain qualified executive search consultants; the condition of the economies in the United States, Europe, or elsewhere; social or political instability in markets where we operate; the impact of foreign currency exchange rate fluctuations; price competition; the ability to forecast, on a quarterly basis, variable compensation accruals that ultimately are determined based on the achievement of annual results; our ability to realize our tax loss carry forwards; the timing of a partial release or full reversal of deferred tax asset valuation allowance; the mix of profit and loss by country; an impairment of our goodwill and other intangible assets; and delays in the development and/or implementation of new technology and systems. Our reports filed with the U.S. Securities and Exchange Commission also include information on factors that may affect the outcome of forward-looking statements. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:
Thomas Liddle
Communications Consultant
Tel: + 61-2-8205-2376
Email: tliddle@heidrick.com

Eric Sodorff
Director, Corporate Communications
Tel: +1-312-496-1613
Email: esodorff@heidrick.com
SOURCE Heidrick & Struggles International, Inc.

Reports of increased survival in bird flu patients taking Tamiflu

These data reinforce the World Health Organization (WHO) advisory that Tamiflu is the only antiviral strongly recommended for the treatment of humans infected with the H5N1 virus. The physicians' report was revealed this week at the International Symposium on Respiratory Viral Infections (ISRVI) in Singapore.(1)

According to the WHO the H5N1 virus has already killed 234 people in 12 countries.(2)

Tamiflu is the only antiviral reported to have been used against H5N1 in humans outside the laboratory and actually in the field.

In Indonesia, of the total of 119 H5N1 human cases reported, 22 survived - an 18 percent survival rate overall. Of these, 33 patients received no Tamiflu, all of whom died. Tamiflu was administered to 86 patients with a 26 percent survival rate overall. Time from onset of illness to initiation of treatment appeared to influence survival. Of the 2 patients who received Tamiflu within 24 hours of illness onset both survived. 55 percent survived if given the drug within four days (6/11), and 35 percent survived if given Tamiflu within six days (13 37)(3).

The survival rate of those receiving it later than 6 days after illness onset was 18 percent (9/49).(2)

Recent information on 8 Vietnamese patients infected with H5N1, was also presented. All 8 patients received Tamiflu. However, all 8 patients presented to the hospital later than 5 days after onset of illness. Only 3 of the 8 patients survived reinforcing that treatment benefit is reduced for patients that receive the drug later in the course of illness. (3,4) In 2 patients who were unable to take the drug orally due to the severity of their illness physicians administered the drug by nasogastric tube and found it was well absorbed and there was a reduction in H5N1 virus in these patients.

Susceptibility of circulating H5N1 strains to Tamiflu

These clinical findings are supported by new animal data, also presented at ISRVI, which shows that oseltamivir treatment was effective against H5N1 influenza viruses representing different clades/subclades. However higher doses were required for the more pathogenic H5N1 viruses.(5)

"Multiple factors can affect the susceptibility of antiviral therapy with highly pathogenic H5N1 influenza viruses and it is reassuring that oseltamivir, in mouse models, demonstrates activity even to the most pathogenic circulating strains," comments study author Dr. Elena Govorkova, St. Jude Children's Research Hospital, Memphis, US. "Antiviral drugs are an essential component for the early control of an influenza pandemic."

Data also confirms the low level of resistance reported to date with Tamiflu to H5N1 avian influenza in the field; there are only five cases of published reports of H5N1 resistance or reduced susceptibility to Tamiflu to date.(6,7,8)

Laboratory results have shown 96 percent of H5N1 strains (53 out of 55) tested in the laboratory were sensitive to Tamiflu.(9)

This compares to the around 14 percent of isolates tested this year of the seasonal influenza A H1N1 virus showing resistance to Tamiflu, reported at the conference.(10)

It is important to note that these increased levels of resistance have only been reported spontaneously in this year's H1N1 (Solomon Islands) seasonal strain, and not an avian strain such as H5N1 and not in patients who have been administered Tamiflu.(11)

"Currently, we are seeing that Tamiflu has been used as part of the clinical management of patients infected with H5N1 with only isolated cases of resistance being reported," comments Dr David Reddy, Global Pandemic Task Force Leader at Roche. "This is reassuring for governments that have stockpiled Tamiflu for pandemic use. It is however critical that both Roche and the medical community remain vigilant so that we can understand this mutating virus and be best prepared for defence against a potential pandemic strain."

Roche has undertaken several research initiatives to study the use of Tamiflu against the evolving H5N1 avian influenza virus, including collaborations with the National Institutes of Health (NIH), the Southeast Asia Influenza Clinical Trials Research Network and other research institutions.

Note to editors:

Difference between a pandemic strain of influenza and seasonal influenza

A pandemic strain of influenza is always of the A variety and is a completely new strain to which there will be no immunity whereas a seasonal strain of influenza is one that has previously been circulating, which may have changed slightly (antigenic drift) and to which a level of immunity exists.

About pandemic influenza

An influenza pandemic occurs when a new strain of influenza A virus appears, against which the human population has no immunity resulting in several, simultaneous epidemics worldwide with enormous numbers of deaths and illness. The most severe influenza pandemics to date include: 'Spanish flu' A (H1N1): 1918 caused in excess of 30 million deaths worldwide, 'Asian flu' A (H2N2): 1958 caused 1 million deaths worldwide, 'Hong Kong flu' A (H3N2): 1968 caused 800,000 deaths worldwide in six weeks. The WHO believes that we are as close to the next pandemic as we have been any time in the past 37 years, with two of the three widely-recognised prerequisites for a human pandemic met to date in the avian influenza outbreak in East Asia. Firstly, a new influenza virus strain has emerged (H5N1), and secondly, the virus has spread to humans. The final barrier will be the transmission of the virus from human to human.

About Tamiflu

Tamiflu is designed to be active against all clinically relevant influenza viruses and works by blocking the action of the neuraminidase (NA) enzyme on the surface of the virus. When neuraminidase is inhibited, the spread of the virus to other cells in the body is inhibited. It is licensed for the treatment and prophylaxis of influenza in children aged one year and above and in adults. The most frequently reported adverse events in clinical studies were nausea, vomiting, and diarrhea. Tamiflu is available for the treatment of influenza in more than 80 countries worldwide.

Tamiflu was approved based on studies in seasonal influenza. The magnitude of effect of Tamiflu in treating and preventing novel strains of influenza (such as those that may be involved in a pandemic or associated with avian flu) cannot be predicted. The WHO has recommended that higher doses and longer duration may be required

Roche and Gilead

Tamiflu was invented by Gilead Sciences and licensed to Roche in 1996. Roche and Gilead partnered on clinical development, with Roche leading efforts to produce, register and bring the product to the markets. Under the terms of the companies' agreement, amended in November 2005, Gilead participates with Roche in the consideration of sub-licenses for the pandemic supply of Tamiflu in resource-limited
countries. To ensure broader acess to Tamiflu for all patients in need, Gilead has agreed to waive its right to full royalty payments for product sold under these sub-licenses.

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, a market leader in virology and active in other major therapeutic areas such as autoimmune diseases, inflammation, metabolism and central nervous system.

Additional information
- Roche Health Kiosk, Influenza: www.health-kiosk.ch start_grip.htm
- About Tamiflu: www.roche.com/med_mbtamiflu05e.pdf
- About influenza: www.roche.com/med_mbinfluenza05e.pdf
- WHO: Global influenza programme: www.who.int/csr/disease influenza/en/
- WHO: Avian flu: www.who.int/mediacentre/factsheets avian_influenza/en/

References
(1) Antivirals and therapeutics session, X International symposium on Respiratory Viral infections, Singapore, Sunday 2nd March 2008
(2) World Health Organization. Cumulative Number of Confirmed Human Cases of Avian Influenza A/(H5N1) Reported to WHO. 28 February 2008 http://www.who.int/csr/disease avian_influenza/country/cases_table_2008_02_28/ en/index.html
(3) Sedyaningsih ER. The Indonesian Experience, X International symposium on Respiratory Viral infections, Singapore, Sunday 2nd March 2008
(4) Wertheim HFI. The recent Vietnamese Experience, X International symposium on Respiratory Viral infections, Singapore, Sunday 2nd March 2008
(5) Govorkova E. Influenza Antivirals in H5N1 Disease, Animal Model, X International symposium on Respiratory Viral infections, Singapore, Sunday 2nd March 2008
(6) Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus. Update on Avian Influenza A (H5N1) Virus Infection in Humans. N Engl J Med 358;3
(7) de Jong MD, Thanh TT, Khanh TH, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005;353:2667-72
(8) Saad MD, Boynton BR, Earhart KC, et al. Detection of oseltamivir resistance mutation N294S in humans with influenza A H5N1. In: Program and abstracts of the Options for the Control of Influenza Conference, Toronto, June 17-23, 2007:228. abstract.
(9) Hurt AC. et al. Susceptibility of highly pathogenic (H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Research 73 (2007) 228-231
(10) World Health Organization. Influenza A (H1N1) virus resistance to oseltamivir - Last quarter 2007 to 28 February 2008. 28 February 2008. http://www.who.int/csr/disease/influenza H1N1ResistanceWeb20080228.pdf
(11) World Health Organization. WHO/ECDC frequently asked questions for Oseltamivir Resistance. Last updated 15 February 2008.

SOURCE: Roche
CONTACT: Helen Walicka, International Communications Manager,
+41-(0)-79-263-9701/
Web site: http://www.roche.com /